What is ONCO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ONCO?

P/E (TTM) is n/a and 52-week range is $0.58 to $209.50 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ONCO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ONCO?

The company profile lists revenue (TTM) near $1M, net income (TTM) near $-1.80B, EPS (TTM) near $-200.08 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Onconetix Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cincinnati, Ohio, US, 4M shares outstanding, ISIN US68237Q3020 when available from company profile and filing metadata.

Onconetix Inc

$ONCO

Health Care · Biotechnology

IR Run Scenarios

$0.62

-5.24%

Onconetix Inc

$ONCO

Health Care · Biotechnology

IR Run Scenarios

$0.62

-5.24%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 2 full-time employees. The company went IPO on 2022-02-18. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

Employees

2

Website

www.onconetix.com/

IPO

2022-02-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US68237Q3020

Headquarters

Cincinnati, Ohio, US

Shares outstanding

4M

NAICS sector

Manufacturing

Institutional ownership

7.33%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 2 full-time employees. The company went IPO on 2022-02-18. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

Employees

2

Website

www.onconetix.com/

IPO

2022-02-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)